Viridian seeks Priority Review for veligrotug, aiming for a potential mid-2026 commercial launch if approved. Global phase 3 ...
AAVantgarde Bio has announced the successful closing of a $141 million (€122 million) Series B financing round that was co-led by a new lead, Schroders Capital, as well as existing investors Atlas ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback